Cis-Diamminedichloroplatinum (II) in the Treatment of Refractory Epidermoid Carcinomas of the Head and Neck Region
Publication Information Expand/Collapse
1981
Cis-platinum (CACP) toxicity. An analysis based on 3 Southwest Oncology Group studies.
Cis-platinum (CACP) toxicity. An analysis based on 3 Southwest Oncology Group studies.
Cis-platinum (CACP) toxicity. An analysis based on 3 Southwest Oncology Group studies.
1980
Cis-platinum therapy of previously treated head and neck cancer: The Southwest Oncology Group's two-dose per month outpatient regimen.
1979
Cis-dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group studies.
Cis-dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group studies.
Cis-dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group studies.
Cis-dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group studies.
Cis-dichlorodiammineplatinum (II) in adult patients: Southwest Oncology Group studies.
1978
Effectiveness of new out patient program utilizing CACP in the chemotherapy of advanced epidermoid head and neck tumors.
Effectivenes of a two-dose regimen utilizing cis-diammine- dichloride platinum (II) in the treatment of refractory epidermoid carcinomas of the head and neck region. A Southwest Oncology Group study.